An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2021 financial and operating results on the evening of Thursday, March 24th.
Following the press release, Celyad management will host a conference call on Friday, March 25th at 1 p.m. CET / 8 a.m. ET to discuss full year 2021 results and provide an update on the Company’s recent progress and upcoming milestones.
Participants may access the conference call by dialing +1-412-317-6060 (International), +1-866-652-5200 (United States) or +32 (0) 800-38913 (Belgium).
To access the live webcast and archived recording, visit the "Events" section of the Celyad website.
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Forward-Looking Statement
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding: the KEYNOTE-B79 trial and the clinical hold. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).